Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

AbbVie : New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:11pm CEST

New Findings Reported from AbbVie Describe Advances in Biochemistry [Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation]

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Chemistry - Biochemistry. According to news reporting out of North Chicago, Illinois, by NewsRx editors, research stated, "Cancer cells have an unusually high requirement for the central and intermediary metabolite nicotinamide adenine dinucleotide (NAD(+)), and NAD(+) depletion ultimately results in cell death. The rate limiting step within the NAD(+) salvage pathway required for converting nicotinamide to NAD(+) is catalyzed by nicotinamide phosphoribosyltransferase (NAMPT)."

Our news journalists obtained a quote from the research from AbbVie, "Targeting NAMPT has been investigated as an anti-cancer strategy, and several highly selective small molecule inhibitors have been found to potently inhibit NAMPT in cancer cells, resulting in NAD(+) depletion and cytotoxicity. To identify mechanisms that could cause resistance to NAMPT inhibitor treatment, we generated a human fibrosarcoma cell line refractory to the highly potent and selective NAMPT small molecule inhibitor, GMX1778. We uncovered novel and unexpected mechanisms of resistance including significantly increased expression of quinolinate phosphoribosyl transferase (QPRT), a key enzyme in the de novo NAD(+) synthesis pathway. Additionally, exome sequencing of the NAMPT gene in the resistant cells identified a single heterozygous point mutation that was not present in the parental cell line. The combination of upregulation of the NAD(+) de novo synthesis pathway through QPRT over-expression and NAMPT mutation confers resistance to GMX1778, but the cells are only partially resistant to next-generation NAMPT inhibitors."

According to the news editors, the research concluded: "The resistance mechanisms uncovered herein provide a potential avenue to continue exploration of next generation NAMPT inhibitors to treat neoplasms in the clinic."

For more information on this research see: Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation. Biochemical and Biophysical Research Communications, 2017;491(3):681-686. Biochemical and Biophysical Research Communications can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Biochemical and Biophysical Research Communications - www.journals.elsevier.com/biochemical-and-biophysical-research-communications/)

Our news journalists report that additional information may be obtained by contacting T.H. Huang, AbbVie Inc, North Chicago, IL 60064, United States. Additional authors for this research include L.T. Lam, K.L. Longenecker, M.H. Bui, K.B. Idler, K.B. Glaser, J.L. Wilsbacher, C. Tse, W.N. Pappano and J. Guo (see also Chemistry - Biochemistry).

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Biochemistry, Chemistry, Oncology, Genetics, Cancer, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
10/19 ABBVIE : Researchers from AbbVie Report Findings in Medicinal Chemistry [Are We ..
10/19 ENANTA PHARMACEUTICALS : Announces Data to be Presented on AbbVie's MAVYRET&trad..
10/19 ABBVIE (NYSE : ABBV) Discloses Collaboration With Harpoon Therapeutics To Conduc..
10/18 ABBVIE : and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboratio..
10/18 ABBVIE : to Present at the 2017 Credit Suisse Health Care Conference
10/13 ABBVIE : obtains licence for Turnstone Biologics oncolytic viral immunotherapies
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
More news
News from SeekingAlpha
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% pr..
10/17 FFF PORTFOLIO : Nam Tai Takes Off And Adding Qualcomm
10/16 BIOTECH FORUM DAILY DIGEST : Aratana Therapeutics Back In The Spotlight
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 932 M
Net income 2017 7 351 M
Debt 2017 25 677 M
Yield 2017 2,69%
P/E ratio 2017 20,25
P/E ratio 2018 16,46
EV / Sales 2017 6,42x
EV / Sales 2018 5,68x
Capitalization 154 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target -4,0%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.37%153 097
MERCK KGAA-4.68%14 409
KYOWA HAKKO KIRIN CO LTD24.78%10 167
JAZZ PHARMACEUTICALS PLC28.83%8 437
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 792
CONVATEC GROUP-9.02%5 572